Abstract: SA-PO885
Midodrine Is Effective in the Management of Intradialytic Hypotension Among Critically-Ill Patients with AKI (A Randomized Clinical Trial
Session Information
- Dialysis: Cardiovascular, BP, Volume
October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Imam, Mahmoud Hamada, Faculty of medicine,Benha University, Benha, Egypt
- Shawki, Mohammed, Faculty of medicine,Benha University, Benha, Egypt
- Essawy, Tareq, Faculty of medicine,Benha University, Benha, Egypt
Background
Intradialytic hypotension commonly occurs among critically ill patients. Different tools were exploited to mitigate IDH. Midodrine showed promising results in small interventional studies. There was no randomized clinical trial to assess the efficacy of midodrine. This study aims to evaluate the effectiveness of midodrine in a randomized placebo-controlled study among critically ill patients.
Methods
Eighty intensive care unit patients were eligible for this study. After IDH episode, they were randomized to either midodrine tablets or placebo. The count of IDH episodes, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lowest blood pressure were recorded. Mortality and adverse effects were recorded for both groups. The duration of the study was 30 days.
Results
eventy-five patients completed the study. Midodrine significantly decreased the count of IDH episodes. Both SBP and DBP were significantly higher among midodrine group. There was a reduction in mortality with midodrine therapy; the reduction was statistically insignificant (p = 0.43). The drug was tolerable with no adverse effects.
Conclusion
Oral midodrine therapy yielded beneficial results and was an adequate tool for management of IDH among critically-ill patients with the AKI.